STOCK TITAN

[Form 3] SOLESENCE, INC. Initial Statement of Beneficial Ownership

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
3

Solesence, Inc. reported an initial Form 3 disclosing that Laura C. Riffner became Chief Financial Officer and received an option to purchase 60,000 shares of common stock on 09/03/2025. The option vests in three equal annual installments beginning 09/03/2026 and expires on 09/03/2032, with a strike price set at the NASDAQ closing price on the grant date. The filing was signed on 10/06/2025 and notes delays due to CIK availability and EDGAR Next technical issues.

Solesence, Inc. ha comunicato una Form 3 iniziale che indica che Laura C. Riffner è diventata Chief Financial Officer e ha ricevuto un'opzione per acquistare 60.000 azioni comuni al prezzo di esercizio stabilito in base al prezzo di chiusura NASDAQ nel giorno di emissione, relativo al 09/03/2025. L'opzione vesti in tre rate annuali uguali a partire dal 09/03/2026 e scade il 09/03/2032, con un prezzo di esercizio fissato al prezzo di chiusura NASDAQ nel giorno di concessione. Il deposito è stato firmato il 10/06/2025 e segnala ritardi dovuti alla disponibilità del CIK e a problemi tecnici di EDGAR Next.

Solesence, Inc. informó un Formulario 3 inicial que revela que Laura C. Riffner se convirtió en Directora Financiera y recibió una opción para comprar 60,000 acciones ordinarias en la fecha 09/03/2025. La opción vence en tres cuotas anuales iguales a partir de 09/03/2026 y expira el 09/03/2032, con un precio de ejercicio establecido al precio de cierre de NASDAQ en la fecha de la concesión. La presentación fue firmada el 10/06/2025 y señala retrasos debido a la disponibilidad del CIK y a problemas técnicos de EDGAR Next.

Solesence, Inc.Laura C. Riffner 가 최고재무책임자(CFO)가 되었고 60,000 주의 보통주를 매수할 수 있는 옵션을 받았음을 초기 Form 3에 공시했다. 옵션은 09/03/2025에 발효되며, 3회 동일한 연간 분할로 09/03/2026부터 가속 vesting 되고 09/03/2032에 만료되며 행사가격은 부여일의 NASDAQ 종가로 설정된다. 제출은 10/06/2025에 서명되었고 CIK 가용성과 EDGAR Next 기술 문제로 인한 지연을 언급한다.

Solesence, Inc. a publié un Form 3 initial indiquant que Laura C. Riffner est devenue directrice financière et a reçu une option d'achat pour 60 000 actions ordinaires à la date 09/03/2025. L'option vest en trois versements annuels égaux à partir du 09/03/2026 et expire le 09/03/2032, avec un prix d'exercice fixé au cours de clôture NASDAQ à la date d'octroi. Le dépôt a été signé le 10/06/2025 et note des retards dus à la disponibilité du CIK et à des problèmes techniques d'EDGAR Next.

Solesence, Inc. meldete ein erstes Form 3-Dokument, in dem Laura C. Riffner zur Chief Financial Officer wurde und eine Option zum Kauf von 60.000 Stammaktien am 09/03/2025 erhalten hat. Die Option wird in drei gleichen jährlichen Raten begünstigt 09/03/2026 und läuft am 09/03/2032 aus, mit einem Ausübungspreis, der zum NASDAQ-Schlusskurs am Ausgabedatum festgelegt ist. Die Einreichung wurde am 10/06/2025 unterzeichnet und erwähnt Verzögerungen aufgrund der Verfügbarkeit von CIK und technischer Probleme von EDGAR Next.

Solesence, Inc. أبلغت عن نموذج 3 ابتدائي يكشف أن Laura C. Riffner أصبحت المدير التنفيذي المالي وتلقت خياراً لشراء 60,000 سهماً عادياً في التاريخ 09/03/2025. يتم vesting الخيار على ثلاث دفعات سنوية متساوية ابتداءً من 09/03/2026 وتنتهي صلاحيتها في 09/03/2032، مع سعر الإضراب المحدد عند سعر إغلاق NASDAQ في تاريخ المنحة. تم التوقيع على الإيداع في 10/06/2025 ويشير إلى تأخيرات بسبب توفر CIK ومشاكل فنية في EDGAR Next.

Solesence, Inc. 在初步的 Form 3 中披露,Laura C. Riffner 已成为首席财务官,并在 09/03/2025 获得购买 60,000 股普通股的期权。该期权自 09/03/2026 起以三期等额分期归属,并于 09/03/2032 到期,行使价按授予日 NASDAQ 收盘价设定。该备案于 10/06/2025 签署,并提及因 CIK 可用性和 EDGAR Next 技术问题而导致的延迟。

Positive
  • Experienced CFO hire signaled by appointment of Laura C. Riffner
  • Long-dated equity incentive (expiration 09/03/2032) aligns executive and shareholder interests
Negative
  • Filing delay due to missing CIK and EDGAR Next technical issues
  • Vesting conditional on continued employment, creating potential forfeiture risk if tenure is short

Insights

New CFO received a standard multi‑year option package aligning pay with tenure.

The grant of 60,000 options with a three‑year vesting schedule is a common structure to link executive compensation to continued service and potential share price appreciation. The strike price is tied to the NASDAQ closing price on 09/03/2025, which makes the award performance‑neutral at grant and valuable only if the share price rises.

Key dependencies include the company’s stock performance over the next 3 years and continued employment through each vesting date; the option expires on 09/03/2032. Investors can monitor dilution impact and any further grants in subsequent filings within the next 12–36 months.

Solesence, Inc. ha comunicato una Form 3 iniziale che indica che Laura C. Riffner è diventata Chief Financial Officer e ha ricevuto un'opzione per acquistare 60.000 azioni comuni al prezzo di esercizio stabilito in base al prezzo di chiusura NASDAQ nel giorno di emissione, relativo al 09/03/2025. L'opzione vesti in tre rate annuali uguali a partire dal 09/03/2026 e scade il 09/03/2032, con un prezzo di esercizio fissato al prezzo di chiusura NASDAQ nel giorno di concessione. Il deposito è stato firmato il 10/06/2025 e segnala ritardi dovuti alla disponibilità del CIK e a problemi tecnici di EDGAR Next.

Solesence, Inc. informó un Formulario 3 inicial que revela que Laura C. Riffner se convirtió en Directora Financiera y recibió una opción para comprar 60,000 acciones ordinarias en la fecha 09/03/2025. La opción vence en tres cuotas anuales iguales a partir de 09/03/2026 y expira el 09/03/2032, con un precio de ejercicio establecido al precio de cierre de NASDAQ en la fecha de la concesión. La presentación fue firmada el 10/06/2025 y señala retrasos debido a la disponibilidad del CIK y a problemas técnicos de EDGAR Next.

Solesence, Inc.Laura C. Riffner 가 최고재무책임자(CFO)가 되었고 60,000 주의 보통주를 매수할 수 있는 옵션을 받았음을 초기 Form 3에 공시했다. 옵션은 09/03/2025에 발효되며, 3회 동일한 연간 분할로 09/03/2026부터 가속 vesting 되고 09/03/2032에 만료되며 행사가격은 부여일의 NASDAQ 종가로 설정된다. 제출은 10/06/2025에 서명되었고 CIK 가용성과 EDGAR Next 기술 문제로 인한 지연을 언급한다.

Solesence, Inc. a publié un Form 3 initial indiquant que Laura C. Riffner est devenue directrice financière et a reçu une option d'achat pour 60 000 actions ordinaires à la date 09/03/2025. L'option vest en trois versements annuels égaux à partir du 09/03/2026 et expire le 09/03/2032, avec un prix d'exercice fixé au cours de clôture NASDAQ à la date d'octroi. Le dépôt a été signé le 10/06/2025 et note des retards dus à la disponibilité du CIK et à des problèmes techniques d'EDGAR Next.

Solesence, Inc. meldete ein erstes Form 3-Dokument, in dem Laura C. Riffner zur Chief Financial Officer wurde und eine Option zum Kauf von 60.000 Stammaktien am 09/03/2025 erhalten hat. Die Option wird in drei gleichen jährlichen Raten begünstigt 09/03/2026 und läuft am 09/03/2032 aus, mit einem Ausübungspreis, der zum NASDAQ-Schlusskurs am Ausgabedatum festgelegt ist. Die Einreichung wurde am 10/06/2025 unterzeichnet und erwähnt Verzögerungen aufgrund der Verfügbarkeit von CIK und technischer Probleme von EDGAR Next.

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Riffner Laura C

(Last) (First) (Middle)
1319 MARQUETTE DRIVE

(Street)
ROMEOVILLE IL 60446

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
09/03/2025
3. Issuer Name and Ticker or Trading Symbol
SOLESENCE, INC. [ SLSN ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Common Stock (right to purchase 09/03/2026(1) 09/03/2032 Common Stock 60,000 $3.5 D
Explanation of Responses:
1. Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.
Remarks:
Ms. Riffner began employment with Solesence, Inc. on September 3, 2025. This option grant was effective that day, with the strike price based upon the closing NASDAQ market price that same day. We did not have Ms. Riffner's CIK number available to complete this filing timely, this was compounded by technical issues relating to the adoption of EDGAR Next.
/s/ Laura C. Riffner 10/06/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 3 filed for Solesence (SLSN) disclose?

It discloses that Laura C. Riffner was appointed CFO and granted an option to buy 60,000 shares on 09/03/2025, vesting in three equal annual installments and expiring on 09/03/2032.

When do Ms. Riffner's options begin to vest?

Vesting begins on 09/03/2026 and occurs in three equal annual installments subject to certain restrictions.

What is the strike price for the option grant?

The strike price was set equal to the NASDAQ closing market price on 09/03/2025 (the filing states the price was based on that closing price).

Why was the Form 3 filed on 10/06/2025 rather than sooner?

The filing notes delays due to lacking Ms. Riffner's CIK number and technical issues related to adoption of EDGAR Next.

How long do the options remain exercisable?

The options expire on 09/03/2032.
Solesence

NASDAQ:SLSN

SLSN Rankings

SLSN Latest News

SLSN Latest SEC Filings

SLSN Stock Data

258.67M
18.88M
73.21%
6.24%
1.31%
Household & Personal Products
Perfumes, Cosmetics & Other Toilet Preparations
Link
United States
ROMEOVILLE